ArticlePloS one2014
Estrogen regulates the tumour suppressor MiRNA-30c and its target gene, MTA-1, in endometrial cancer.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Circulating miRNA as diagnostic tools for gynecological diseases and their applications in biosensor development.Analytical and bioanalytical chemistry · 2026Review
- Diagnostic and prognostic potential of microRNA profiles in endometrioid endometrial cancer.Scientific reports · 2025Article
- The Effect of Arsenic Trioxide and Its Combination with Oxaliplatin and Docetaxel on the Induction of Autophagy and Expression of LC3 and Beclin-1 Genes in AGS and MKN-45 Gastric Cancer Cell Lines.Advanced pharmaceutical bulletin · 2025Article
- Combining Chemotherapy Agents and Autophagy Modulators for Enhanced Breast Cancer Cell Death.Advanced pharmaceutical bulletin · 2024Article
- Metastasis-associated protein 1: A potential driver and regulator of the hallmarks of cancer.Journal of biosciences · 2022Review
- Expression Profiles of Estrogen-Regulated MicroRNAs in Cancer Cells.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Long non-coding RNA NNT-AS1 positively regulates NPM1 expression to affect the proliferation of estrogen-mediated endometrial carcinoma by interacting.Journal of Cancer · 2022Article
- Association ofIndian journal of clinical biochemistry : IJCB · 2021Article
- Non-Coding RNAs as Prognostic Markers for Endometrial Cancer.International journal of molecular sciences · 2021Review
- Review
- The Central Roles of Noncoding RNA in Estrogen-Dependent Female Reproductive System Tumors.International journal of endocrinology · 2021Review
- Downregulation of miR-30c-5p expression in colorectal cancer tissue is sex-dependent.Physiological research · 2020Article
- MTA1, a Target of Resveratrol, Promotes Epithelial-Mesenchymal Transition of Endometriosis via ZEB2.Molecular therapy. Methods & clinical development · 2020Article
- Effects of Sorafenib and Arsenic Trioxide on U937 and KG-1 Cell Lines: Apoptosis or Autophagy?Cell journal · 2020Article
- Long non-coding RNA CASC7 is associated with the pathogenesis of heart failure via modulating the expression of miR-30c.Journal of cellular and molecular medicine · 2020Article
- Role of MicroRNA-30c in cancer progression.Journal of Cancer · 2020Review
- Review
- Article
- miR-940 potentially promotes proliferation and metastasis of endometrial carcinoma through regulation of MRVI1.Bioscience reports · 2019Article
- Expression of miR-30c and BCL-9 in gastric carcinoma tissues and their function in the development of gastric cancer.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA-30c (miR-30c) has been reported to be a tumour suppressor in endometrial cancer (EC). We demonstrate that miR-30c is down-regulated in EC tissue and is highly expressed in estrogen receptor (ER)-negative HEC-1-B cells. MiR-30c directly inhibits MTA-1 expression and functions as a tumour suppressor via the miR-30c-MTA-1 signalling pathway. Furthermore, miR-30c is decreased upon E2 treatment in both ER-positive Ishikawa and ER-negative HEC-1-B cells. Taken together, our results suggest that miR-30c is an important deregulated miRNA in EC and might serve as a potential biomarker and novel therapeutic target for EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.